Crizotinib is effective in shrinking tumors in patients with anaplastic lymphoma receptor tyrosine kinase positive non-small cell lung cancer, a cancer commonly found in people who never smoked, and should be the standard of care for advanced stages of this disease, according to research presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology.
- Advanced lung cancer patients see improved, progression-free survivalThu, 13 Nov 2008, 10:51:04 EST
- Identifying lung cancer gene markers shows promise in identifying patients needing chemoThu, 9 Dec 2010, 10:08:22 EST
- Research demonstrates differing genetic makeup of lung cancer in African-American patientsThu, 13 Nov 2008, 10:50:58 EST
- Tissue analyses indicate survival benefits for some lung cancer patientsThu, 13 Nov 2008, 10:51:06 EST
- Gene testing identifies lung cancer patients who benefit from ALK-inhibitor drugTue, 12 Jan 2010, 17:24:30 EST